Quanterix Corp (NASDAQ:QTRX) Expected to Post Quarterly Sales of $14.18 Million
Brokerages expect that Quanterix Corp (NASDAQ:QTRX) will post $14.18 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Quanterix’s earnings. The highest sales estimate is $15.15 million and the lowest is $13.30 million. Quanterix posted sales of $10.88 million in the same quarter last year, which suggests a positive year over year growth rate of 30.3%. The business is scheduled to issue its next quarterly earnings results on Monday, March 16th.
According to Zacks, analysts expect that Quanterix will report full year sales of $55.14 million for the current year, with estimates ranging from $54.63 million to $55.87 million. For the next financial year, analysts forecast that the firm will report sales of $70.84 million, with estimates ranging from $68.05 million to $74.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Quanterix.
Several brokerages have issued reports on QTRX. Zacks Investment Research upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Wednesday, January 8th. BidaskClub upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Friday, February 7th. Canaccord Genuity reiterated a “buy” rating and set a $35.00 price objective on shares of Quanterix in a research report on Thursday, November 7th. Finally, ValuEngine cut shares of Quanterix from a “buy” rating to a “hold” rating in a research report on Thursday, January 16th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $31.33.
In other news, Director Martin D. Madaus sold 1,600 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $25.25, for a total transaction of $40,400.00. Following the completion of the sale, the director now directly owns 8,149 shares in the company, valued at $205,762.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO E Kevin Hrusovsky sold 6,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $22.17, for a total transaction of $144,105.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,168 shares of company stock valued at $1,660,503. 30.80% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of QTRX. Metropolitan Life Insurance Co NY acquired a new stake in Quanterix in the third quarter worth $78,000. Citigroup Inc. grew its holdings in Quanterix by 258.8% in the fourth quarter. Citigroup Inc. now owns 4,941 shares of the company’s stock worth $117,000 after purchasing an additional 3,564 shares during the period. Royal Bank of Canada grew its holdings in Quanterix by 116.4% in the second quarter. Royal Bank of Canada now owns 6,285 shares of the company’s stock worth $213,000 after purchasing an additional 3,380 shares during the period. Alpine Global Management LLC acquired a new stake in Quanterix in the fourth quarter worth $207,000. Finally, Victory Capital Management Inc. grew its holdings in Quanterix by 90.1% in the fourth quarter. Victory Capital Management Inc. now owns 9,800 shares of the company’s stock worth $266,000 after purchasing an additional 4,646 shares during the period. Institutional investors own 70.53% of the company’s stock.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
See Also: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.